Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
Health Technology Assessment · 2025
DOI: 10.3310/mbva3675 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Health Technology Assessment, 2025. Verfasst von Cherry-Ann Waldron und 24 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacterial Infections, Procalcitonin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Procalcitonin is a biomarker specific for bacterial infection, with a more rapid response than other commonly used biomarkers, such as C-reactive protein, but it is not routinely used in the National Health Service.
Objective
To determine if using a procalcitonin-guided algorithm may safely reduce duration of antibiotic therapy compared to standard of care in hospitalised children with suspected or confirmed infection.
Design
A pragmatic, multicentre, open-label, parallel two-arm, individually randomised controlled trial with internal pilot phase, qualitative study and health economic evaluations.
Setting
Paediatric wards or paediatric intensive care units within children’s hospitals ( n = 6) and district general hospitals ( n = 9) in the United Kingdom.
Participants
Children aged between 72 hours and 18 years admitted to hospital and being treated with intravenous antibiotics for suspected or confirmed bacterial infection.
Interventions
Procalcitonin-guided algorithm versus usual standard care alone. Main outcome measures Coprimary outcomes were duration of intravenous antibiotic use and a composite safety measure.
Results
Between 11 June 2018 and 12 October 2022, 1949 children were recruited: 977 to the procalcitonin group [427 female (43.7%), 550 male (56.3%)], and 972 to the usual care group [478 female (49.2%), 494 male (50.8%)]. Duration of intravenous antibiotics was not significantly different between the procalcitonin group (median 96.0 hours) and the usual care group (median 99.7 hours) [hazard ratio = 0.96 (0.87, 1.05)], and the procalcitonin-guided algorithm was non-inferior to usual care [risk difference = −0.81% (95% confidence interval upper bound 1.11%)]. At clinical review, a procalcitonin result was available for 81.8% of the time, which was considered as part of clinical decision-making 66.6% of the time, and the algorithm was adhered to 57.2% of the time. Incremental cost-effectiveness ratio per duration of intravenous antibiotics hour avoided from bootstrapped samples was £467.62 per intravenous antibiotic hour avoided. Cost analysis of complete cases was also higher in the procalcitonin arm for all age groups, and for children aged 5 years and over. The intervention is not cost-effective as it is more expensive with no significant improvement in intravenous antibiotic duration.
Limitations
Robust antimicrobial stewardship programmes were already implemented in the lead recruiting sites, and adherence to the algorithm was poor. Clinicians may be reluctant to adhere to biomarker-guided algorithms, due to unfamiliarity with interpreting the test result.
Conclusions
In children hospitalised with confirmed or suspected bacterial infection, the addition of a procalcitonin-guided algorithm to usual care is non-inferior in terms of safety, but does not reduce duration of intravenous antibiotics, and is not cost-effective. In the presence of robust antimicrobial stewardship programmes to reduce antibiotic use, a procalcitonin-guided algorithm may offer little added value. Future work Future trials must include an implementation framework to improve trial intervention fidelity, and repeated cycles of education and training to facilitate implementation of biomarker-guided algorithms into routine clinical care.
Trial registration
This trial is registered as ISRCTN11369832. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 15/188/42) and is published in full in Health Technology Assessment ; Vol. 29, No. 16. See the NIHR Funding and Awards website for further award information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Trials Research, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, UK.
- Division of Population Medicine, School of Medicine, Cardiff University, Heath Park, Cardiff, UK.
- Division of Health Research, Lancaster University, Lancaster, UK.
- University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Hospital for Children, Bristol, UK.
- NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
- Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
ORCID-Profile: Cherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, Debbie Harris, Lucy Brookes-Howell, Céu Mateus, Jolanta Bernatoniene, Katrina Cathie, Saul N Faust, Josie Henley, Lucy Hinds, Kerry Hood, Chao Huang, Sarah Kotecha, Sarah Milosevic, Helen Nabwera, Sanjay Patel, Stéphane Paulus, Colin Ve Powell, Jenny Preston, Huasheng Xiang, Emma Thomas-Jones, Enitan D Carrol
Förderung
- Health Technology Assessment programme
Zitieren
APA
Waldron, C. A., Pallmann, P., Schoenbuchner, S., Harris, D., Brookes-Howell, L., Mateus, C., Bernatoniene, J., Cathie, K., Faust, S. N., Henley, J., Hinds, L., Hood, K., Huang, C., Jones, S., Kotecha, S., Milosevic, S., Nabwera, H., Patel, S., Paulus, S., …, & BATCH trial team (2025). Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT. Health Technology Assessment. https://doi.org/10.3310/mbva3675
Vancouver
Waldron CA, Pallmann P, Schoenbuchner S, Harris D, Brookes-Howell L, Mateus C, et al. Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT. Health Technology Assessment. 2025. doi:10.3310/mbva3675
BibTeX
@article{Waldron2025,
author = {Waldron, Cherry-Ann and Pallmann, Philip and Schoenbuchner, Simon and Harris, Debbie and Brookes-Howell, Lucy and Mateus, Céu and Bernatoniene, Jolanta and Cathie, Katrina and Faust, Saul N and Henley, Josie and Hinds, Lucy and Hood, Kerry and Huang, Chao and Jones, Sarah and Kotecha, Sarah and Milosevic, Sarah and Nabwera, Helen and Patel, Sanjay and Paulus, Stéphane and Powell, Colin Ve and Preston, Jenny and Xiang, Huasheng and Thomas-Jones, Emma and Carrol, Enitan D and BATCH trial team, BATCH trial team},
title = {Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT},
journal = {Health Technology Assessment},
year = {2025},
doi = {10.3310/mbva3675}
}
EUVIMED